Deep-learning based automated quantification of critical optical coherence tomography features in neovascular age-related macular degeneration

Eye (Lond). 2024 Feb;38(3):537-544. doi: 10.1038/s41433-023-02720-8. Epub 2023 Sep 5.

Abstract

Purpose: To validate a deep learning algorithm for automated intraretinal fluid (IRF), subretinal fluid (SRF) and neovascular pigment epithelium detachment (nPED) segmentations in neovascular age-related macular degeneration (nAMD).

Methods: In this IRB-approved study, optical coherence tomography (OCT) data from 50 patients (50 eyes) with exudative nAMD were retrospectively analysed. Two models, A1 and A2, were created based on gradings from two masked readers, R1 and R2. Area under the curve (AUC) values gauged detection performance, and quantification between readers and models was evaluated using Dice and correlation (R2) coefficients.

Results: The deep learning-based algorithms had high accuracies for all fluid types between all models and readers: per B-scan IRF AUCs were 0.953, 0.932, 0.990, 0.942 for comparisons A1-R1, A1-R2, A2-R1 and A2-R2, respectively; SRF AUCs were 0.984, 0.974, 0.987, 0.979; and nPED AUCs were 0.963, 0.969, 0.961 and 0.966. Similarly, the R2 coefficients for IRF were 0.973, 0.974, 0.889 and 0.973; SRF were 0.928, 0.964, 0.965 and 0.998; and nPED were 0.908, 0.952, 0.839 and 0.905. The Dice coefficients for IRF averaged 0.702, 0.667, 0.649 and 0.631; for SRF were 0.699, 0.651, 0.692 and 0.701; and for nPED were 0.636, 0.703, 0.719 and 0.775. In an inter-observer comparison between manual readers R1 and R2, the R2 coefficient was 0.968 for IRF, 0.960 for SRF, and 0.906 for nPED, with Dice coefficients of 0.692, 0.660 and 0.784 for the same features.

Conclusions: Our deep learning-based method applied on nAMD can segment critical OCT features with performance akin to manual grading.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Deep Learning*
  • Humans
  • Intravitreal Injections
  • Macular Degeneration* / drug therapy
  • Ranibizumab / therapeutic use
  • Retinal Detachment*
  • Retrospective Studies
  • Subretinal Fluid
  • Tomography, Optical Coherence / methods
  • Wet Macular Degeneration* / diagnostic imaging
  • Wet Macular Degeneration* / drug therapy

Substances

  • Angiogenesis Inhibitors
  • Ranibizumab